Minerva is conducting the trial to evaluate the efficacy of MIN-101 compared to placebo in improving the symptoms of schizophrenic patients. This is also the primary endpoint of the trial. Other endpoints include the …

Visit source – 

Minerva's Schizophrenia Drug Application Accepted by FDA – Zacks …